Table of Content




1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview

3. Market Dynamics
3.1. Key Drivers
3.1.1. Growing Number Of Cancer Cases And Mortalities
3.1.2. Increasing Popularity Of Precision Medicines
3.1.3. Rising Number Of Adverse Drug Reaction Cases
3.2. Key Restraints
3.2.1. Country-Specific Reimbursement Issues
3.2.2. Frequent Cases Of Leakage In Companion Diagnostics For Oncology

4. Key Analytics
4.1. Impact Of Covid-19 On Companion Diagnostics Market
4.2. Key Market Trends
4.3. Porter’S Five Forces Analysis
4.3.1. Buyers Power
4.3.2. Suppliers Power
4.3.3. Substitution
4.3.4. New Entrants
4.3.5. Industry Rivalry
4.4. Opportunity Matrix
4.5. Vendor Landscape
4.6. Value Chain Analysis
4.7. Key Buying Criteria
4.8. Regulatory Framework

5. Market By Technology
5.1. In Situ Hybridization
5.2. Polymerase Chain Reaction
5.3. Immunohistochemistry
5.4. Next Generation Sequencing
5.5. Other Technologies

6. Market By Indication
6.1. Oncology
6.2. Neurology
6.3. Infectious Diseases
6.4. Other Indications

7. Market By End-User
7.1. Pharmaceutical And Biopharmaceutical Companies
7.2. Reference Laboratories
7.3. Other End-Users

8. Market By Products & Services
8.1. Assay Kits And Reagents
8.2. Software & Services

9. Geographical Analysis
9.1. North America
9.1.1. Market Size & Estimates
9.1.2. Key Growth Enablers
9.1.3. Key Challenges
9.1.4. Key Players
9.1.5. Country Analysis
9.1.5.1. United States
9.1.5.2. Canada
9.2. Europe
9.2.1. Market Size & Estimates
9.2.2. Key Growth Enablers
9.2.3. Key Challenges
9.2.4. Key Players
9.2.5. Country Analysis
9.2.5.1. United Kingdom
9.2.5.2. Germany
9.2.5.3. France
9.2.5.4. Spain
9.2.5.5. Italy
9.2.5.6. Poland
9.2.5.7. Netherlands
9.2.5.8. Rest Of Europe
9.3. Asia-Pacific
9.3.1. Market Size & Estimates
9.3.2. Key Growth Enablers
9.3.3. Key Challenges
9.3.4. Key Players
9.3.5. Country Analysis
9.3.5.1. China
9.3.5.2. Japan
9.3.5.3. India
9.3.5.4. South Korea
9.3.5.5. Indonesia
9.3.5.6. Singapore
9.3.5.7. Australia & New Zealand
9.3.5.8. Rest Of Asia-Pacific
9.4. Rest Of World
9.4.1. Market Size & Estimates
9.4.2. Key Growth Enablers
9.4.3. Key Challenges
9.4.4. Key Players
9.4.5. Regional Analysis
9.4.5.1. Latin America
9.4.5.2. Middle East & Africa

10. Competitive Landscape
10.1. Key Strategic Developments
10.1.1. Mergers & Acquisitions
10.1.2. Product Launches & Developments
10.1.3. Partnerships & Agreements
10.2. Company Profiles
10.2.1. Abbott Laboratories
10.2.2. Agilent
10.2.3. Alamc Group
10.2.4. Arup Laboratories
10.2.5. Biocartis
10.2.6. Biomerieux Sa
10.2.7. Danaher Corporation
10.2.8. Ge Healthcare
10.2.9. Genomic Health
10.2.10. Illumina Inc
10.2.11. Myriad Genetics Inc
10.2.12. Qiagen Nv
10.2.13. Roche Diagnostics
10.2.14. Sysmex Corporation
10.2.15. Thermo Fisher Scientific Inc



List of Figures

List Of Figures
Figure 1: Cdx Leakage
Figure 2: Key Market Trends
Figure 3: Porter’S Five Forces Analysis
Figure 4: Opportunity Matrix
Figure 5: Vendor Landscape
Figure 6: Value Chain Analysis
Figure 7: Fda Guidelines For Cdx Approval
Figure 8: Global Companion Diagnostics Market, Growth Potential, By Technology, In 2021
Figure 9: Global Companion Diagnostics Market, By In Situ Hybridization, 2022-2030 (In $ Million)
Figure 10: Global Companion Diagnostics Market, By Polymerase Chain Reaction, 2022-2030 (In $ Million)
Figure 11: Global Companion Diagnostics Market, By Immunohistochemistry, 2022-2030 (In $ Million)
Figure 12: Global Companion Diagnostics Market, By Next Generation Sequencing, 2022-2030 (In $ Million)
Figure 13: Global Companion Diagnostics Market, By Other Technologies, 2022-2030 (In $ Million)
Figure 14: Global Companion Diagnostics Market, Growth Potential, By Indication, In 2021
Figure 15: Global Companion Diagnostics Market, By Oncology, 2022-2030 (In $ Million)
Figure 16: Global Companion Diagnostics Market, By Neurology, 2022-2030 (In $ Million)
Figure 17: Global Companion Diagnostics Market, By Infectious Diseases, 2022-2030 (In $ Million)
Figure 18: Global Companion Diagnostics Market, By Other Indications, 2022-2030 (In $ Million)
Figure 19: Global Companion Diagnostics Market, Growth Potential, By End-User, In 2021
Figure 20: Global Companion Diagnostics Market, By Pharmaceutical And Biopharmaceutical Companies, 2022-2030 (In $ Million)
Figure 21: Global Companion Diagnostics Market, By Reference Laboratories, 2022-2030 (In $ Million)
Figure 22: Global Companion Diagnostics Market, By Other End-Users, 2022-2030 (In $ Million)
Figure 23: Global Companion Diagnostics Market, Growth Potential, By Products & Services, In 2021
Figure 24: Global Companion Diagnostics Market, By Assay Kits And Reagents, 2022-2030 (In $ Million)
Figure 25: Global Companion Diagnostics Market, By Software & Services, 2022-2030 (In $ Million)
Figure 26: North America Companion Diagnostics Market, Country Outlook, 2021 & 2030 (In %)
Figure 27: United States Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 28: Canada Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 29: Europe Companion Diagnostics Market, Country Outlook, 2021 & 2030 (In %)
Figure 30: United Kingdom Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 31: Germany Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 32: France Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 33: Spain Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 34: Italy Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 35: Poland Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 36: Netherlands Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 37: Rest Of Europe Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 38: Asia-Pacific Companion Diagnostics Market, Country Outlook, 2021 & 2030 (In %)
Figure 39: China Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 40: Japan Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 41: India Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 42: South Korea Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 43: Indonesia Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 44: Thailand Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 45: Australia & New Zealand Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 46: Rest Of Asia-Pacific Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 47: Rest Of World Companion Diagnostics Market, Regional Outlook, 2021 & 2030 (In %)
Figure 48: Latin America Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 49: Middle East & Africa Companion Diagnostics Market, 2022-2030 (In $ Million)

List of Tables

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - COMPANION DIAGNOSTICS
TABLE 2: NEW CASES OF CANCER PATIENTS IN 2020
TABLE 3: GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 4: GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 5: GLOBAL IN SITU HYBRIDIZATION MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 6: GLOBAL IN SITU HYBRIDIZATION MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 7: GLOBAL POLYMERASE CHAIN REACTION MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 8: GLOBAL POLYMERASE CHAIN REACTION MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 9: GLOBAL IMMUNOHISTOCHEMISTRY COMPANION DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 10: GLOBAL IMMUNOHISTOCHEMISTRY COMPANION DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 11: GLOBAL NEXT GENERATION SEQUENCING MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 12: GLOBAL NEXT GENERATION SEQUENCING MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 13: GLOBAL OTHER TECHNOLOGIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 14: GLOBAL OTHER TECHNOLOGIES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 15: GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 16: GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 17: GLOBAL ONCOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 18: GLOBAL ONCOLOGY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 19: GLOBAL NEUROLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 20: GLOBAL NEUROLOGY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 21: GLOBAL INFECTIOUS DISEASES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 22: GLOBAL INFECTIOUS DISEASES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 23: GLOBAL OTHER INDICATIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 24: GLOBAL OTHER INDICATIONS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 25: GLOBAL COMPANION DIAGNOSTICS MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 26: GLOBAL COMPANION DIAGNOSTICS MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 27: GLOBAL PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 28: GLOBAL PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 29: GLOBAL REFERENCE LABORATORIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 30: GLOBAL REFERENCE LABORATORIES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 31: GLOBAL OTHER END-USERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 32: GLOBAL OTHER END-USERS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 33: GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 34: GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 35: GLOBAL ASSAY KITS AND REAGENTS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 36: GLOBAL ASSAY KITS AND REAGENTS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 37: GLOBAL SOFTWARE & SERVICES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 38: GLOBAL SOFTWARE & SERVICES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 39: GLOBAL COMPANION DIAGNOSTICS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 40: GLOBAL COMPANION DIAGNOSTICS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 41: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 42: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 43: LEADING PLAYERS OPERATING IN NORTH AMERICA COMPANION DIAGNOSTICS MARKET
TABLE 44: EUROPE COMPANION DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 45: EUROPE COMPANION DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 46: LEADING PLAYERS OPERATING IN EUROPE COMPANION DIAGNOSTICS MARKET
TABLE 47: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 48: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 49: LEADING PLAYERS OPERATING IN ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET
TABLE 50: REST OF WORLD COMPANION DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 51: REST OF WORLD COMPANION DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 52: LEADING PLAYERS OPERATING IN REST OF WORLD COMPANION DIAGNOSTICS MARKET
TABLE 53: LIST OF MERGERS & ACQUISITIONS
TABLE 54: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 55: LIST OF PARTNERSHIPS & AGREEMENTS